The Breakthrough after the GLP-1 Diet! How a Pill from Eli Lilly Aims to Stop the yo-yo Effect!
Reading Time: 4 minutes
The weight loss revolution enters its next round. While injection preparations have triggered the GLP-1 boom, a simple pill is now in the spotlight. New phase 3 data on Orforglipron show why Eli Lilly's (LLY) pill has the potential to fundamentally change the long-term treatment of obesity and why investors are paying close attention now. GLP-1 soaring – why the pill is the next big step The market for GLP-1 medications is growing rapidly, driven by the global rise in obesity and type 2 diabetes. Injections like Wegovy or Zepbound have shown...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
